Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02944617 · ClinicalTrials.gov registry record · NA
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor
A NA study of Metastatic Renal Cell Carcinoma and Diarrhea, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02944617 is a NA study of Metastatic Renal Cell Carcinoma and Diarrhea that has completed, run by City of Hope Medical Center. The registered enrollment target is 21 participants, below the 143-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02944617, a NA study of Metastatic Renal Cell Carcinoma and Diarrhea, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized clinical trial studies how well probiotic yogurt supplement works in reducing diarrhea in patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) and that are being treated with vascular endothelial growth factor-tyrosine kinase inhibitor therapy. Studying samples of blood and stool from patients who eat probiotic yogurt and those who avoid probiotic yogurt may help doctors plan better treatment.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DIETARY_SUPPLEMENT Micronutrient-Fortified Probiotic Yogurt
- DRUG VEGF-TKI
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-11-11 |
| Est. Completion | 2021-12-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02944617
The ClinicalTrials.gov registry entry for NCT02944617 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (85% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02944617 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02944617 about?
NCT02944617 is a clinical study titled "Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor". This randomized clinical trial studies how well probiotic yogurt supplement works in reducing diarrhea in patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) and that are being treated with vascular endothelial growth factor-tyrosine kinase inhi...
What is the current status of trial NCT02944617?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2016-11-11. Estimated completion is 2021-12-19.
What conditions does trial NCT02944617 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma, Diarrhea, Stage IV Renal Cell Cancer.
What interventions are being tested in trial NCT02944617?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Micronutrient-Fortified Probiotic Yogurt (DIETARY_SUPPLEMENT), VEGF-TKI (DRUG).
Who is sponsoring clinical trial NCT02944617?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02944617 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
-
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer
RECRUITING · NA
-
App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell Cancer
ACTIVE NOT RECRUITING · NA
-
Cancer and Blood Pressure Management, CARISMA Study
ACTIVE NOT RECRUITING · NA
-
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
COMPLETED · NA
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.